It has been documented that small molecule inhibitors (vemurafenib and dabrafenib) of BRAF V600–mutant induce tumor regression, and combination of BRAF and MEK inhibitors can improve survival rate of melanoma patients [32–34]. The gene discussed is MAP2K7; the disease is melanoma.